Benzinga | Feb 4, 2021 07:27AM EST

Acceleron Expects To Report ~$23M In Royalty Revenue For Q4 From Net Sales Of REBLOZYL, Expects $54.8M In Royalty Revenue For FY20

- Acceleron expects to report approximately $23.0 million in royalty revenue for Q4 2020 from approximately $115 million in net sales of REBLOZYL(r) (luspatercept-aamt) as reported by Bristol Myers Squibb -

- Acceleron expects to report approximately $54.8 million in royalty revenue for full year 2020 from approximately $274 million in net sales of REBLOZYL as reported by Bristol Myers Squibb -

Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL(r) (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $115 million for the fourth quarter and approximately $274 million for the full year ended December 31, 2020.

Acceleron expects to report royalty revenue of approximately $23.0 million from net sales of REBLOZYL in the fourth quarter ended December 31, 2020. This compares with approximately $19.3 million in royalty revenue from approximately $96 million of net sales of REBLOZYL for the third quarter ended September 30, 2020. For the full year 2020, Acceleron expects to report royalty revenue of approximately $54.8 million.

The preliminary unaudited revenue estimates for the quarter and full year ended December 31, 2020 included in this release are the responsibility of management and are subject to the completion of the Company's customary quarter and year-end financial closing procedures, including management's review and finalization, as well as audit procedures by the Company's independent registered public accounting firm, which have not yet been completed. During the course of the Company's review process, items may be identified that would require it to make adjustments, which could result in material changes to the Company's preliminary unaudited estimated financial results. Consequently, these revenue estimates should not be viewed as substitutes for the Company's earnings release and Annual Report on Form 10-K.